Chiara Francesca Magnani1, Andrea Biondi, Ettore Biagi. 1. aDepartment of Pediatrics, Tettamanti Research Center, University of Milano-Bicocca, Milan bSan Gerardo Hospital/Fondazione MBBM, Monza, Italy.
Abstract
PURPOSE OF REVIEW: Allogeneic hematopoietic stem cell transplantation (HSCT) is still partially ineffective in curing high-risk hematological malignancies, with estimates of relapse rates ranging from 40 to 50%. The purpose of this review is to discuss the emerging therapeutic options for patients with relapsed disease following HSCT based on adoptive immunotherapy using donor-derived T cells genetically engineered to express CD19-specific chimeric antigen receptors (CARs). RECENT FINDINGS: Adoptive cell therapy (ACT) with CAR-modified T cells represents an attractive therapeutic option for further enhancing the graft-versus-leukemia effect. However, CAR-modified T cells are often obtained using apheresis products collected from the patient's own blood, a procedure that has hindered the application of CAR-based therapies into the clinic. Alternative approaches rely on CAR T cells derived from donors rather than the patient's own blood. Therefore, it appears that overcoming the practical limitation of allogeneic T cell-induced graft versus-host-disease is a key to providing access to CAR immunotherapy to all eligible patients. SUMMARY: Donor-derived CD19-CAR T cells may advance the field of CAR immunotherapy by controlling relapse in leukemic patients and improving the range of applications of ACT protocols.
PURPOSE OF REVIEW: Allogeneic hematopoietic stem cell transplantation (HSCT) is still partially ineffective in curing high-risk hematological malignancies, with estimates of relapse rates ranging from 40 to 50%. The purpose of this review is to discuss the emerging therapeutic options for patients with relapsed disease following HSCT based on adoptive immunotherapy using donor-derived T cells genetically engineered to express CD19-specific chimeric antigen receptors (CARs). RECENT FINDINGS: Adoptive cell therapy (ACT) with CAR-modified T cells represents an attractive therapeutic option for further enhancing the graft-versus-leukemia effect. However, CAR-modified T cells are often obtained using apheresis products collected from the patient's own blood, a procedure that has hindered the application of CAR-based therapies into the clinic. Alternative approaches rely on CAR T cells derived from donors rather than the patient's own blood. Therefore, it appears that overcoming the practical limitation of allogeneic T cell-induced graft versus-host-disease is a key to providing access to CAR immunotherapy to all eligible patients. SUMMARY:Donor-derived CD19-CAR T cells may advance the field of CAR immunotherapy by controlling relapse in leukemicpatients and improving the range of applications of ACT protocols.
Authors: Chiara F Magnani; Nice Turazzi; Fabrizio Benedicenti; Andrea Calabria; Erika Tenderini; Sarah Tettamanti; Greta M P Giordano Attianese; Laurence J N Cooper; Alessandro Aiuti; Eugenio Montini; Andrea Biondi; Ettore Biagi Journal: Oncotarget Date: 2016-08-09
Authors: Chiara F Magnani; Sarah Tettamanti; Gaia Alberti; Ilaria Pisani; Andrea Biondi; Marta Serafini; Giuseppe Gaipa Journal: Cells Date: 2020-05-27 Impact factor: 6.600